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Abstract
Background: Although the MMP-2 promoter lacks a canonical progesterone response element
(PRE), the hormone inhibits MMP-2 expression and is part of treatment protocols in gynecological
invasive pathologies, including endometriosis and endometrial hyperplasia. This study aimed to
explore the mechanism by which progesterone inhibits MMP-2 expression.
Methods: The effect of progesterone on MMP-2 expression in the JAR human choriocarcinoma
cell line was analyzed by gelatin zymography. MMP-2 transcript expression was studied using
Northern blot and semi-quantitative RT-PCR. Rat promoter deletion analysis, electrophoretic
mobility shift and chromatin immuno-precipitation assays were performed in order to locate the
DNA binding site and the transcription factors involved in MMP-2 regulation.
Results:  Progesterone significantly decreased secretion of pro-MMP-2 and MMP-2 transcript
expression level in a dose-dependent manner. Progesterone (1 microM) significantly decreased
both human and rat MMP-2 promoter activity (80.1% +/- 0.3 and 81.3% +/- 0.23, respectively).
Progesterone acts through the SP1 family transcription factors-binding site, located between -1433
and -1342 bp region from the transcriptional start site of the rat MMP-2 promoter, which are
present in the orthologous human MMP-2 promoter. Progesterone receptor (PR), SP2, SP3 and
SP4 proteins are constitutively bound to this consensus sequence.
Conclusion:  Progesterone reducesPR and SP4 binding to the MMP-2 promoter, thereby
suppressing transcription. Progesterone also promotes SP4 degradation. These novel mechanisms
of MMP-2 regulation by progesterone provide the biological rationale for the use of progesterone
in clinical settings associated with increased MMP-2 expression.
Background
Matrix metalloproteinase-2 (MMP-2) plays a critical role
in invasion, metastasis, angiogenesis and tissue remodel-
ling [1]. The protein is widely expressed by a number of
normal and transformed cells [2]. Recent studies have
highlighted the important role of MMP-2 in the invasive
potential of metastatic endometrial [3,4], ovarian [5] and
trophoblast cells [6], as well as invasion of the normal tro-
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phoblast [7]. The ability of trophoblasts to infiltrate the
uterine wall and to anchor the placenta to it, as well as
their ability to infiltrate and adjust utero-placental vessels
to pregnancy, is dependent upon MMP-2 secretion [8].
Abnormal MMP-2 secretion can also result in impaired
implantation and is closely linked to several gestational
pathologies, including repeated abortion [9], preeclamp-
sia [10], gestational trophoblastic neoplasia and preterm
labor [11,12]. The activity of MMP-2 is regulated at multi-
ple levels, including gene transcription, translation,
proenzyme activation and inhibition by the tissue inhibi-
tors of metalloproteinases [13]. An extensive body of data
has demonstrated a complex transcriptional regulatory
network operative during both normal development and
disease [[14-17], and [18]]. The human, and orthologous
rat and murine MMP-2 proximal promoters lack a canon-
ical TATA box and are composed of a relatively GC-rich
region adjoining multiple transcriptional start sites. Func-
tional binding sites for numerous transcription factors,
including AP-1, AP-2, p53, nm-23β, and SP1/3 have been
reported [14-19].
MMP-2 transcription is also regulated by reproductive
hormones. Several studies have demonstrated induction
of MMP-2 by estrogen in a variety of tissues, including vas-
cular smooth muscle cells, glomerular mesangial cells and
granulosa-lutein cells [20-22]. Estrogen responsiveness of
human MMP-2 transcription was mapped to a half-palin-
dromic binding site for the estrogen receptor (ERE), the
activity of which was affected by an adjacent single nucle-
otide polymorphism [23]. In contrast, we, and others,
have demonstrated that progesterone (PG) inhibits MM-2
expression in a variety of tissues [7,24-27]. This inhibitory
effect of PG on MMP-2 expression occurs in the absence of
a canonical progesterone response element (PRE) in the
MMP-2 promoter. Progesterone has been part of the treat-
ment protocol in number of conditions associated with
enhanced MMP-2 secretion, including endometrial hyper-
plasia, imminent abortion and as luteal support in
assisted reproduction [28-30]. Progesterone is also used as
prophylactic treatment in women with a previous history
of preterm labor [31].
Given the clinical importance of MMP-2 regulation by
progesterone, we examined the transcriptional regulation
of MMP-2 by progesterone using the model human JAR
choriocarcinoma cell line. Our results support a novel
mechanism by which progesterone inhibits MMP-2
expression. Within the context of human choriocarci-
noma JAR cells basal transcription of MMP-2 is mediated
by binding of primarily transcription factor SP4 to the
MMP-2 proximal promoter. Progesterone suppresses
MMP-2 transcription by reducing progesterone receptor
(PR) and SP4 binding to the MMP-2 promoter. The inhib-
itory effect of progesterone on MMP-2 transcription may
also result from enhanced proteasomal degradation of
SP4/SP2.
Methods
Materials
Culture media and fetal calf serum (FCS) were obtained
from Biological industries, Beit-Ha'Emek, Israel. Proges-
terone (P4) and Mifepristone (RU486) were obtained
from Sigma (St. Louis, MO, USA); Antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The BCA assay kit was obtained from Bio-Rad Lab-
oratories, Inc, USA. All of the other reagents, unless other-
wise specified, were purchased from Sigma.
Cell culture
Human choriocarcinoma cell line (JAR) was obtained
from the American Type Culture Collection (Manassas,
VA). Cells were maintained in M199 medium containing
10% FCS in 60 mm culture plates, 24 wells and 96 wells
kept in a humidified (37°C, 5% CO2) chamber. For the
experiments described below, cells were trypsinized and
harvested on reaching 80% to 90% confluence. The incu-
bation period was 6–48 hours in the absence or presence
of 0.1–10 μM progesterone (water soluble p-7556, Sigma,
USA), and 10-6 M Mifepristone (RU486, Sigma, USA) in
serum free M-199 medium supplemented 1% penicillin/
streptomycin and kept in 5% CO2 at 37°C.
Gelatin zymography
To detect proteolytic activity in conditioned media col-
lected after 48–72 h of culture, substrate gel electrophore-
sis (zymography) on gels containing gelatin as the
substrate were used as described previously [7]. Identifica-
tion of each gelatinase band was done in accordance to
their molecular weight and commercial standards (gelati-
nize A and B, 7 μl; Oncogene Science; data not shown).
These bands (pro-MMP) were quantified using the BioIm-
aging gel documentation system (Dinco & Renum)
endowed with TINA software (Raytest). The MMP secre-
tion was expressed as a percentage of the control value.
Western blot analysis
Western blot analysis was conducted as described previ-
ously [7]. To detect SP1, SP2, SP3, SP4, PR ubiquitin and
GAPDH (for normalization), cell extracts (30 μg/lane)
were diluted with 4× sample buffer (5% SDS and 20%
glycerol in 0.4 M Tris, pH 6.8, containing 0.02%
bromophenol blue) and subjected to 10% polyacryla-
mide gel electrophoresis. Transfer and blocking were per-
formed as reported [7]. Blocked membranes were
incubated for 1 h with either mouse anti-human SP1, SP2,
SP3, SP4, ubiquitin and GAPDH antibody (1.0 μg/ml;
Santa Cruz Biotechnology) or rabbit anti-human PR pol-
yclonal antibody (1.0 μg/ml; sc-539; Santa Cruz Biotech-
nology) in 10% non-fat milk and Tris-buffered salineReproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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containing 0.01% Tween-20. The membranes were subse-
quently washed with Tris-buffered saline containing 0.5%
Tween-20 and incubated for 1 h with horseradish peroxi-
dase-conjugated anti-mouse rabbit secondary antibody
(Jackson ImmunoResearch) in 10% non-fat milk and Tris-
buffered saline containing 0.01% Tween-20, then
detected by enhanced chemiluminescence (Amersham
International) and quantified by densitometry as above.
Protein assay
The total protein content of trophoblast cells was deter-
mined using a protein assay kit with BSA as the standard
(Bio-Rad Laboratories, Inc. USA).
Immunofluorescence
JAR cells were washed 3 times with PBS and fixed with
3.7% paraformaldehyde in PBS for 20 minutes at room
temperature (RT) and then permeabilized for 3 minutes
with 0.1% Triton X-100 in PBS. Incubation for 1 hour
with blocking buffer (PBS supplemented with 3% FCS
serum) and three washings in PBS. The cells were then
incubated with primary antibodies (anti-SP4, sc-645 (3 μl
into 700 μl PBS supplemented with 1.5% FCS), for 30
minutes at RT, followed by additional five washings in
PBS. Cells were incubated in the dark for 30 minutes at RT
with fluorescein-labelled phalloidin (AlexaFluor-488, A-
12379, Molecular Probes) for F-actin (3 μl into 700 μl PBS
supplemented with 1.5% FCS) and the secondary goat
anti-rabbit IgG antibodies were conjugated with Alexa
Fluor-546 (1 μl into 700 μl PBS supplemented with 1.5%
FCS, A-11035, Molecular Probes) or secondary goat anti-
mouse IgG antibodies were conjugated with AlexaFluor-
633 (1 μl into 700 μl PBS supplemented with 1.5% FCS,
A-21052, Molecular Probes). Following washing in PBS,
stained cells were photographed using a confocal micro-
scope. The photos were analyzed by Image Pro software
that quantifies density per area.
Semiquantitative RT-PCR
Reverse transcription-polymerase chain reaction was con-
ducted with the following primers: MMP-2: forward, 5'-
ACCTGGATGC-CGTCGTGGAC-3'; reverse, 5'-
GTGGCAGCACCAGGGCAGC-3' (447-bp product). For
normalization, we used the levels of the housekeeping
gene GAPDH with the following primers: forward, 5'-
TGATGACATCAAGAAGGTGGTGAAG-3'; reverse, 5'-
TCCTTGGAGGCCATGTGGGCCAT-3' (240-bp product).
Total RNA was extracted from frozen samples with TRIzol
reagent according to the manufacturer's instructions (Life
Technologies, Inc.-BRL). The RNA concentrations were
determined spectrophotometrically. A RT kit (Superscript
preamplification system; Life Technologies, Inc.-BRL) was
used in the synthesis and amplification of cDNA. Total
RNA (5 μg) was denatured at 70°C for 10 min and then
reverse transcribed in the presence of 25 ng/μl of oligo
(deoxythymidine) primer (Life Technologies, Inc.), 2.5
mM MgCl2, 0.5 mM deoxy-NTPs, 10 mM dithiothreitol,
and 10 U of ribonuclease H-reverse transcriptase (Super-
script II RT; Life Technologies, Inc.) for 60 min at 42°C
and 5 min at 95°C. Subsequently, 10 μl of the resulting
cDNA were used as a template for PCR. The PCR was set
up using 3 mM MgCl2, 50 pmol of each primer, and 2.5 U
of Taq DNA polymerase (Sigma). The PCR conditions
were 94°C for 2 min, followed by 35 cycles of 94°C for 30
sec, 60°C for 45 sec, and 72°C for 60 sec, with a 72°C
extension for 10 min. After PCR, the products were
resolved on a 2.5% agarose ethidium bromide gel. Images
were captured with Polaroid film and quantified using
BioImaging gel documentation system (Dinco & Renum)
endowed with TINA software (Raytest).
Plasmids
Firefly luciferase reporter plasmids incorporating either
the human or rat MMP-2 promoters were prepared using
the promoterless luciferase expression vector, pGL2-Basic
(Promega). The human promoter pGL2-MMP-2 construct
(denoted HpGL2-MMP2) extended to -1659 bp relative to
the transcriptional start site was provided kindly by Dr.
E.N. Benveniste [18]. The rat promoter pGL2-MMP-2 con-
struct (denoted RpGL2-MMP-2) extended to -1686 bp rel-
ative to the translational start site. Serial deletion
constructs of the RpGL2-MMP-2 extended to 1007, 573,
383, 321, 267 bp relative to the translational start site. A
second series of serial deletion constructs extended from
1686 bp to 1433 bp, 1345 bp, 1262 bp and 1181 bp.
Transient transfection and luciferase assays
Cells were transfected as described elsewhere in detail [7].
Briefly, 24 h before transfection, cells were plated in 24 or
96-well plates at a density of 6 × 105 cells per well. Cells
were transfected by LipofectAMINE/Plus Reagent (Invitro-
gen) with full length or constructs plasmids (4 μg) or
PGL2-basic (empty vector). The transfection was per-
formed on JAR cells according to the manufacturer's direc-
tions (Invitrogen). Progesterone (1 μM) was added
immediately after transfection. Luciferase assays of result-
ant cell lysates were performed 6 h after progesterone
treatment according to the manufacturer's instructions
(Promega Corp.). Luciferase reporter enzyme activity was
determined by correcting for β-galactosidase and cell
extract protein content as determined by the Bradford
assay. Results from four independent experiments, each
with duplicate wells, were averaged and presented as the
mean ± SEM.
Nuclear extract preparation
Nuclear and cytosolic extract proteins were prepared from
the cell culture after the incubation period. Culture were
lysed with ice-cold lysis buffer (10 mM Hepes [pH 7.9], 10Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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mM KCL, 1 mM EDTA, 1 mM dithiotheitol, 1 mM PMSF,
10 μg/ml of leupeptin, and 50 μg/ml of aprotinin). Sus-
pensions were incubated for 15 min in 4°C, and Nonidet
P-40 at a 0.4% final concentration was added. The cell sus-
pension was centrifuged for 1 minute at 3000 rpm at 4°C,
the supernatant containing the cytosolic fraction was
removed; and the pellet was resuspended in the same lysis
buffer, which contained 400 mM NaCl instead of KCl.
After 15 min of incubation, the pellet suspensions were
centrifuged for 5 min at 12000 rpm at 4°C. The nuclear
extract was collected and stored at -20°C together with the
cytosolic fraction until use.
Electrophoretic mobility shift assay
SP1 family of transcription factor activities were assessed
by EMSA using double-stranded oligonucleotides corre-
sponding to the SP1 consensus sequences (SP1, Santa
Cruz Biotechnology, USA: sc-2501), or corresponding
with the relevant SP1 binding site in the human promoter
(5'-TCCTGCGGGGCAAGGTCCCTC-CAAGAGGGTCCTT-
3') (Figure 1) Oligonucleotides were labelled with digoxi-
genin (Roche) using Terminal Transferase according to
manufacturer's instructions in dig-labelling kit (Roche,
Dyn Diagnostics Israel). Binding reactions were con-
ducted by incubation of 6 μg of nuclear extract from JAR
cells with digoxigenin-labelled oligonucleotide probes at
30°C for 30 min. in binding buffer containing 15 mM
Hepes, 90 mM KCL, 6% glycerol, 3 mM DTT, 0.5 μg Poly
[d (I-C)] and 0.4 ng oligonucleotide. To each sample 2.5
ml of loading buffer was added (60% TBE 0.25, 40% glyc-
erol). Subsequently, DNA-protein complexes were sepa-
rated from unbound oligonucleotides on a pre-
electrophoresed 6% polyacrylamide gel and electrotrans-
ferred to positively charged nylon membranes (Roche,
Dyn Diagnostics Israel). The DNA-protein complexes
were fixed by baking 30 min at 120°C. Bands were
detected with anti-digoxigenin-AP antibody and the
chemiluminescent substrate CSPD (both Roche, Dyn
Diagnostics Israel) on X-ray film. Sequence specificity of
nuclear protein-oligonucleotide interaction was con-
firmed by competition with a mutated sequence (SP1,
Santa Cruz Biotechnology, sc-2503) that was added to
nuclear extracts for 10 minutes before addition of labelled
probe.
Chromatin immunoprecipitation (ChIP) Assay
Cells were fixed with 1% formaldehyde at 37°C for 10
min. Cells were washed twice with ice-cold PBS with pro-
tease inhibitors (1 mM phenylmethylsulphonyl fluoride,
1 μg/ml aprotinin, and 1 μg/ml pepstatin A), scraped and
pelleted by centrifugation at 4°C. Cells were resuspended
in a lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-
HCl, pH 8.1), incubated for 10 min on ice, and sonicated
to shear DNA. After sonication, lysate was centrifuged for
10 min at 13,000 rpm at 4°C. The supernatant was
diluted in CHIP dilution buffer (0.01% SDS, 1% Triton X-
100, 2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM
NaCl, and protease inhibitors). Primary antibodies were
added and incubated overnight at 4°C with rotation. The
immuno-complex was collected by protein A/G agarose
beads and washed with low salt washing buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 200 mM Tris-HCl,
pH 8.1, and 150 mM NaCl), high-salt buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 200 mM Tris-HCl, pH 8.1,
and 500 mM NaCl), LiCl washing buffer (0.25 M LiCl, 1%
NP40, 1% deoxycolate, 1 mM EDTA, and 10 mM Tris-
HCl, pH 8.1), and finally 1' TE buffer (10 mM Tris-HCl,
and 1 mM EDTA, pH 8.0). After that, the immuno-com-
plex was eluted by the elution buffer (1% SDS, 0.1 M
NaHCO3, and 200 mM NaCl) and the cross-links were
reversed by heating at 65°C for 6 h. After reaction, the
samples were adjusted to 10 mM EDTA, 20 mM Tris-HCl,
pH 6.5, and 40 μg/ml proteinase K, and incubated at
45°C for 1 h. DNA was recovered and was subjected to
PCR amplification of the rat MMP-2 promoter which con-
tains the SP1 site at the -1433/-1342 bp region compli-
ance with human promoter (Figure 1). The sequences for
the primers are: forward 5-ATCACTGGCTCTC-
CAACTTGG-3,; reverse 5-TTAGCTCGCAAGGAGTCTCTT-
3. The predicted size for the PCR product is 250 bp.
Ubiquitinated SP4 protein immuno-precipitation
JAR cells were seeded into 60 mm tissue culture plates in
maintenance medium and allowed to grow to approxi-
mately 90% confluence. Cells were treated with progester-
one 1 μM for 2 h. Whole-cell extracts for the control and
treatment group were obtained using RIPA buffer (50 mM
Tris-HCL, 1% Nonidet P-40, 0.25% sodium deoxycholate,
150 mM NaCl, and 1 mM EDTA) with the addition of pro-
tease inhibitor cocktail. Duplicate aliquots of 500 μg were
used for the experiments. Cell extracts were diluted in ice-
cold PBS containing protease inhibitor cocktail to a final
volume of 1 ml, followed by the addition of 30 μl of pro-
tein A/G PLUS-agarose beads (Santa Cruz, USA). The reac-
tions were placed on a rocker at 4°C for 3 h, followed by
600 g centrifugation at 4°C for 5 min. A 900-μl aliquot of
supernatant from each sample was transferred into a new
Eppendurf tube on ice. Rabbit polyclonal anti-Sp4 (1 μg),
SP1 (1 μg), SP2 (1 μg), SP3 (1 μg), or normal rabbit IgG
(1 μg) was added to either control or treatment set, fol-
lowed by the addition of 30 μl of protein A/G PLUS-agar-
ose beads. The samples were then placed on a rocker at
4°C overnight, followed by centrifugation at 2500 rpm at
4°C for 5 min. The supernatant was removed by aspira-
tion and the immuno-precipitates were washed with two
cycles of 1 ml of ice-cold RIPA buffer followed by 1 ml of
ice-cold PBS using centrifugation at 600 g at 4°C for 5
min. The agarose pellet was resuspended in 40 μl of load-
ing buffer, boiled, and centrifuged. The supernatant was
separated by SDS-10% PAGE, electrophoresed. Total pro-Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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Alignment of human and rat MMP-2 promoters Figure 1
Alignment of human and rat MMP-2 promoters. Bold sequences represent primers used for chromatin immunoprecipi-
tation. Boxed sequence details oligonucleotide sequence used for EMSA studies; underline sequences are the conserved SP1 
consensus binding sites.Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
Page 6 of 12
(page number not for citation purposes)
tein (input) was tested for either, SP1, SP2, SP3, SP4, PR,
ubiquitin and GAPDH. The immuno-precipitant was
tested for the presence of ubiquitin.
Statistical analysis
Results are expressed as the mean ± SEM of 3 to 4 inde-
pendent experiments where each treatment was per-
formed in duplicate. Statistical analysis was performed
using the SPSS statistical software, guided by the statisti-
cian annalist from our central statistical centre. A level of
P < 0.05 was considered to be significant.
Results
Progesterone inhibits MMP-2 expression by JAR 
choriocarcinoma cells
The effect of progesterone on MMP-2 expression in JAR
human choriocarcinoma cell line was conducted. JAR
cells (2 × 105) were incubated 48 h in the absence or pres-
ence of progesterone (0.1–10 μM), and media were ana-
lyzed by zymography for gelatinase secretion.
Progesterone significantly decreased secretion of pro-
MMP-2 in a dose-dependent manner (P < 0.05). Incuba-
tion with progesterone (1,10 μM) decreased pro-MMP-2
secretion by 22 percent (P < 0.01) and by 58.7 percent (P
< 0.01) respectively (control 3245 ± 360, 1 μM 2530 ± 246
10 μM 1340 ± 201). Incubation of progesterone with 10-6
M Mifepristone, a progesterone antagonist, abolished the
inhibitory effect of progesterone on pro-MMP-2 (Figure
2A).
The time course of progesterone-dependent regulation of
MMP-2 gene expression was examined. Transcript expres-
sion of MMP-2 in JAR choriocarcinoma trophoblast cells
treated with progesterone for several time intervals is pre-
Progesterone suppresses JAR MMP-2 secretion and synthesis Figure 2
Progesterone suppresses JAR MMP-2 secretion and synthesis. (A) Secretion of pro-MMP-2 by JAR cells after 48 hours 
incubation in the absence or presence of progesterone alone (1 μM–10 μM) or in combination with Mifepristone (MI; 10-6 M). 
Results represent mean ± SEM from 4 independent experiments *P < 0.05 versus untreated cells. Total RNA of MMP-2 iso-
lated form JAR cells treated with progesterone (1 μM) for the indicated times was assessed by Northern blot (B) and semi-
quantitative reverse transcription-PCR (C). The data are presented as the ratio of MMP-2 to GAPDH. The values represent 
the mean ± SEM from 4 different experiments performed in duplicates.Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
Page 7 of 12
(page number not for citation purposes)
sented using Northern blot (Figure 2B) and semi-quanti-
tative RT-PCR (Figure 2C). Progesterone (1 μM)
significantly decreased MMP-2 transcript expression level
in a time-response manner (P < 0.05). To compare MMP2
mRNA relative expression levels between groups, we ana-
lyzed the ratio of each independent experiment between
the expression level of either MMP2 and the house keep-
ing gene GAPDH from the same tissue under the same
treatment. Inhibition was observed after 4 h of incuba-
tion.
Progesterone inhibits MMP-2 via transcriptional 
repression
We next performed MMP-2 promoter activity assays to
determine if the suppression of MMP-2 synthesis by pro-
gesterone occurs at the transcriptional level. Maximal
inhibition of human MMP-2 promoter activity was
observed with 1 μM progesterone (Figure 3A). Following
incubation of progesterone and 10-6  M Mifepristone
inhibitory effect of progesterone was abolished (Figure
3A). Similar and significant decreases in both rat and
human MMP-2 promoter activities were observed follow-
ing the addition of 1 μM progesterone (80.1% ± 0.3 and
81.3% ± 0.23, respectively, P < 0.01, Figure 3B). Thus, pro-
gesterone inhibits MMP-2 synthesis by direct transcrip-
tional repression.
Progesterone suppresses MMP-2 promoter activity via SP1 
site
Potential regulatory regions in the rat MMP-2 promoter
responsible for the inhibition by progesterone were ana-
lyzed in a series of 5-deletion constructs. A full length rat
MMP-2 luciferase reporter construct (-1686 bp), or
defined deletions constructs, were transfected into JAR
cells treated in the absence or the presence of progesterone
(1 μM). As shown in Figure 4A, addition of progesterone
significantly decreased luciferase reporter activity in the
region between -1007 bp and -1686 bp relative to the
MMP-2 translational start site.
In MMP-2 5'-deletion construct extending to -1502 bp the
inhibitory effect of progesterone was slightly reduced,
however in the -1433 bp deletion construct progesterone
significantly increased its ability to inhibit luciferase activ-
MMP-2 luciferase reporter activities: effects of progesterone Figure 3
MMP-2 luciferase reporter activities: effects of progesterone. (A) JAR cells transfected with control pGL2 vector or 
pGL2 vector containing the human MMP-2 promoter in the presence or absence of progesterone (1 μM–10 μM) or in combi-
nation with RU486 (MI, 10–6 M). (B) JAR cells transfected with pGL2 containing the full length (1686 bp) human or rat promot-
ers in the absence or presence of progesterone (1 μM). Results represent mean ± SEM from four independent experiments; * 
P < 0.05. Black bars: human MMP-2 promoter; white bars: rat MMP-2 promoter.Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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ity (153 ± 10.1 versus 101.2 ± 7.1 percent; P < 0.05), (Fig-
ure 4B). This inhibitory effect of progesterone was
abolished in the -1342 bp deletion construct (92.8 ± 12
and 119.3 ± 11 percent of luciferase activity; P < 0.05). The
progesterone-responsive element should be therefore
located between -1432 to -1342 bp region of the rat-
MMP-2 promoter. In the -1262 bp and -1181 bp deletion
constructs no effect of progesterone was observed.
Transcription factor binding site analysis [32] localized
three potential SP1 binding sites in this sequence that is
conserved in the homologous human MMP-2 promoter
sequence (Figure 1). The sequence analyses suggest that
the inhibitor effect of progesterone on MMP-2 transcrip-
tion may involve interaction of members of the SP1 tran-
scription factor family with specific binding sites in the 91
bp sequence extending between -1433 and -1342 bp of
the rat MMP-2 promoter and the corresponding region of
the human MMP-2 promoter.
EMSA was performed to explore the interaction of SP1
family of transcription factors with these sites. As demon-
strated in Figure 5, the nuclear proteins extracted from JAR
cells formed DNA-protein complex with the DNA probe
corresponding to the SP1 oligonucleotide corresponding
with the relevant sequence in the human promoter (Fig-
ure 5). DNA-protein complex was decreased in the pres-
ence of progesterone (1 μM). The addition of mutant
DNA probes effectively reduced the signal intensity of the
DNA-protein complex. Similar was obtained with SP1 oli-
gonucleotide corresponding with the consensus binding
site of SP1 (data not shown).
Progesterone reduces transcription factors binding to the 
response element on the MMP-2 promoter
The effect of progesterone (1 μM) was studied by ChIP
assay of the classical SP1 family of transcription factors
and the PR. Cells were fixed by formaldehyde, and soluble
chromatin was purified by sonication of cross-linked
Serial deletion mapping of region in rat MMP-2 promoter responsible for progesterone inhibition of MMP-2 transcription Figure 4
Serial deletion mapping of region in rat MMP-2 promoter responsible for progesterone inhibition of MMP-2 
transcription. (A) Coarse promoter deletion mapping; (B) Fine promoter deletion mapping. (C) Sequence from -1433 to 
1342 bp containing progesterone-response region and three potential SP1 binding sites (underlined). White bars: untreated 
cells (control); black bars: treated cells with progesterone (1 μM).Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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nuclei. Chromatin fragments in the range of 500–1000 bp
were immunoprecipitated by specific antibodies (SP1,
SP2, SP3, SP4 and PR). Purified genomic DNA from
immunoprecipitated chromatin was subjected to semi-
quantitative PCR using primers covering the 250-bp -
1433/-1342 region of the rat-MMP-2  promoter corre-
sponded with human promoter (Figure 1). Immunopre-
cipitation by IgG was used as a negative control. Input of
both the control and progesterone treated cells revealed
similar amounts of GAPDH (as internal control, Figure
6A). In the control cells, SP3 and SP1 bands were mini-
mally detectable, while SP2 and SP4 bands were readily
evident. PR was also found to bind to the same region in
the MMP-2 promoter. Thus, in the basal state in an intrin-
sic genomic context, the MMP-2 promoter is occupied by
primarily SP2/PR and SP4/PR complexes. In the presence
of progesterone there was a reduction in SP4 and in PR
binding to the DNA. No significant change was observed
in SP1, SP2 and SP3 following progesterone treatment.
Therefore, progesterone reduces basal MMP-2 transcrip-
tion primarily through a reduction of SP4/PR complex
binding to the intrinsic MMP-2 promoter.
In order to study the possible mechanism for the reduc-
tion in SP4 binding following progesterone treatment,
western blot for the classical SP1 family was performed
with and without progesterone. Results (Figure 6B) show
that SP1, SP2, SP3 and SP4 are expressed in JAR cells. Fol-
lowing treatment with progesterone only SP4 expression
is reduced significantly. These results suggested that pro-
gesterone not only affects SP4/PR binding to the intrinsic
MMP-2 promoter but may also affect SP4 protein levels,
per se.
Role of progesterone on SP4 degradation
To test the possibility that the reduction of SP4 protein
reflects enhancement in its degradation rate rather then,
synthesis inhibition, cells were exposed to cycloheximide
(CHX; 10 μg/ml), a syntactic protein inhibitor, in the
presence or absence of progesterone. The addition for 1
hour of progesterone alone or progesterone with CHX
reduced SP4 expression (Figure 7A) indicating that the
reduction in SP4 expression is most probably due to SP4
degradation. The addition of RU486 did not change the
progesterone effect on SP4 expression, suggesting a non-
classical role for progesterone activity on SP4 degradation.
The effects of progesterone on Ubiquitin binding capacity
to the SP1, SP2, SP3, SP4 and PR proteins were investi-
gated. (Figure 7B). Whole-cell lysates from control and
progesterone-treated groups were initially immunopre-
cipitated with a control IgG or antibodies to SP1, SP2,
SP3, SP4 and PR. Immunoprecipitated fractions were sep-
arated by SDS-polyacrylamide gel electrophoresis and
immunoblotted with anti-ubiquitin antibodies. Antibod-
ies to GAPDH were used as an internal control (data not
shown). The addition of progesterone induced specific
ubiquitin binding only to the SP4 protein.
Discussion
Synthetic progestational agents have been used exten-
sively in invasive gynecological pathologies such as
endometriosis [33] and endometrial hyperplasia [28].
Progesterone is a paradoxical hormone having either
stimulatory or inhibitory effects, depending on the tissue
in question and the dose and treatment regimen [34,35].
Classical P4 activity is mediated by interaction of the hor-
mone with the two classical intracellular progesterone
receptor (PR) isoforms PR-A and PR-B [34,35]. Both iso-
forms, encoded by a single gene independently regulated
by separate promoter, regulate different subsets of genes.
PR frequently acts as ligand-inducible transcription factor
in the respective target cell by binding to specific proges-
terone response elements (PRE) in the promoter of target
genes [36]. The mechanisms of progesterone are only par-
tial explained by their isoforms profile ratio expression.
Recent reports indicate that progesterone can also regulate
promoters lacking a canonical progesterone response ele-
EMSA of JAR cell nuclear extracts with DNA-nuclear protein  complex binding to sequence relevant SP1 binding site in the  human promoter: effect of progesterone Figure 5
EMSA of JAR cell nuclear extracts with DNA-nuclear 
protein complex binding to sequence relevant SP1 
binding site in the human promoter: effect of proges-
terone. Nuclear proteins were isolated from JAR cells cul-
tured with or without progesterone (1 μM). The specificity 
of the DNA-nuclear protein complex was tested by competi-
tion with mutant oligonucleotide. The figure represents five 
separate experiments. The positions of free oligonucleotide 
and shifted oligonucleotide are indicated by arrows.Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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ment [37-40]. In these cases, progesterone receptors interact
indirectly with the promoter through complex formation
with various transcription factors, including several mem-
bers of the SP1 transcription factor family [38,41,37].
We have previously reported that progesterone inhibits
MMP-2 synthesis in reproductive tissues [7]. JAR chorio-
carcinoma cells synthesize high levels of MMP-2, which is
responsible for the highly invasive nature of these cells. In
this report we demonstrate that this inhibitory effect of
progesterone occurs at a transcriptional level in the
absence of a canonical PRE in the human or rat MMP-2
promoters and this inhibitory effect is reversed by Mife-
pristone. Using a combination of techniques, we mapped
the region responsible for high level MMP-2 transcription
in JAR cells to a GC-rich region in the MMP-2 proximal
promoter which contained several potential SP1 tran-
scription family binding sites. In the basal state the MMP-
2 promoter is occupied by SP2/PR and SP4/PR complexes.
Addition of progesterone reduces MMP-2 transcription
through a reduction in SP4 and in PR binding to the
intrinsic MMP-2 promoter.
In addition to displacement of SP4/PR binding from the
MMP-2 promoter, progesterone also affects the net con-
centration of the SP4 protein. Addition of progesterone to
JAR cells specifically promoted degradation of the SP4
protein, while there was no effect on SP1-3 protein degra-
dation. The failure of Mifepristone (progesterone receptor
antagonist) to reverse this progesterone effect, together
with lack of effect by CHX, might suggest that progester-
one is involved, via non classical mechanism, in SP4 pro-
tein degradation rather than inhibition of the protein
synthesis. The ability of progesterone to enhance specific
ubiquitin binding to SP4 protein after four hours incuba-
tion might suggest that ubiquitination of the SP4 protein
would result in enhanced rates of SP4 protein degradation
in the proteasome, thereby reducing SP4 protein levels
and the ability to form transactivating SP4/PR complexes.
Repression of SP4-mediated transactivation via enhanced
proteasomal degradation may be a more common event
than previously recognized. Adelrahim and Safe, [42],
recently demonstrated that cyclooxygenase inhibitors
decrease vascular endothelial cell growth factor expres-
sion via enhanced degradation.
Chromatin immunoprecipitation analysis of SP1-4 and PR interactions with the progesterone regulatory region within a  genomic context Figure 6
Chromatin immunoprecipitation analysis of SP1-4 and PR interactions with the progesterone regulatory 
region within a genomic context. Progesterone reduces JAR nuclear SP4 concentration. (A) Chromatin immunoprecipita-
tion was performed as detailed in Experimental Procedures using sheared chromatin prepared from JAR cells after four hours 
incubation in the presence or absence of progesterone (1 μM). Treatment with progesterone results in decreased binding of 
SP4 and PR to the progesterone regulatory region of the MMP-2 promoter. (B) Western blots of JAR cell nuclear extracts 
from cells after four hours incubation in the presence or absence of progesterone (1 μM). Progesterone treatment specifically 
reduces JAR cell nuclear SP4 levels.Reproductive Biology and Endocrinology 2009, 7:41 http://www.rbej.com/content/7/1/41
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Conclusion
Progesterone reduces PR and SP4 binding to the MMP-2
promoter and promotes SP4 degradation, thereby sup-
pressing MMP-2 promoter transcription. These findings
provides further example for the complex nature of pro-
gesterone-dependent transcriptional regulation, particu-
larly in the absence of a canonical PRE in the proximal
promoter. To our knowledge, the mechanisms of proges-
terone-mediated MMP-2 transcriptional suppression are
unique and provide a firm biological basis for the clinical
application of progesterone in the treatment of gyneco-
logic and obstetric disorders associated with increased
MMP-2 expression.
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